Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 3913-3919

  Gunawardana, Manjula ^a   Remedios Chan, Mariana ^b   Miller, Christine S ^a   Fanter, Rob ^a   Yang, Flora ^a   Marzinke, Mark A ^c   Hendrix, Craig W ^c   Beliveau, Martin ^d   Moss, John A ^a   Smith, Thomas J ^a,b   Baum, Marc M ^a  

^a OAK CREST INSTITUTE OF SCIENCE   (United States)

^b Auritec Pharmaceuticals   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Pharsight A Certara Company   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TENOFOVIR; TENOFOVIR ALAFENAMIDE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG IMPLANT; GS-7340; PRODRUG; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABSENCE OF SIDE EFFECTS; ANIMAL EXPERIMENT; ARTICLE; BEAGLE; BODY WEIGHT; CELL LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DERMAL IMPLANT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; LIMIT OF DETECTION; LOSS OF APPETITE; MALE; NONHUMAN; PRIORITY JOURNAL; SUBDERMAL IMPLANT; SUSTAINED DRUG RELEASE; WEIGHT GAIN; ANALOGS AND DERIVATIVES; ANIMAL; DOG; DRUG EFFECTS; DRUG IMPLANT; EQUIPMENT DESIGN; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MONOCYTE;

ADENINE; ANIMALS; ANTI-HIV AGENTS; DOGS; DRUG IMPLANTS; EQUIPMENT DESIGN; HIV INFECTIONS; HIV-1; MALE; MONOCYTES; PRODRUGS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84931273616     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00656-15     Document Type: Article

References (46)

1. Cohen MS, Smith MK, Muessig KE, Hallett TB, Powers KA, Kashuba AD. 2013. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet 382:1515-1524. http://dx.doi.org/10.1016/S0140-6736(13)61998-4.
2. D'Cruz OJ, Uckun FM. 2014. Vaginal microbicides and their delivery platforms. Expert Opin Drug Deliv 11:723-740. http://dx.doi.org/10.1517/17425247.2014.888055.
3. McGowan I. 2014. An overview of antiretroviral pre-exposure prophylaxis of HIV infection. Am J Reprod Immunol 71:624-630. http://dx.doi.org/10.1111/aji.12225.
4. Muchomba FM, Gearing RE, Simoni JM, El-Bassel N. 2012. State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr 61:490-498. http://dx.doi.org/10.1097/QAI.0b013e31826f9962.
5. Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. 2013. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav 17:2143-2155. http://dx.doi.org/10.1007/s10461-013-0429-9.
6. Gengiah TN, Moosa A, Naidoo A, Mansoor LE. 2014. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm 36:70-85. http://dx.doi.org/10.1007/s11096-013-9861-1.
7. Hendrix CW. 2014. Abstr 2014 Conf Retrovir Opportun Infect, abstr 61.
8. Kruse W, Eggertkruse W, Rampmaier J, Runnebaum B, Weber E. 1991. Dosage frequency and drug compliance behavior - a comparative study on compliance with a medication to be taken twice or 4 times daily. Eur J Clin Pharmacol 41:589-592. http://dx.doi.org/10.1007/BF00314990.
9. Sershen S, West J. 2002. Implantable, polymeric systems for modulated drug delivery. Adv Drug Deliv Rev 54:1225-1235. http://dx.doi.org/10.1016/S0169-409X(02)00090-X.
10. Kutilek VD, Sheeter DA, Elder JH, Torbett BE. 2003. Is resistance futile? Curr Drug Targets Infect Disord 3:295-309. http://dx.doi.org/10.2174/1568005033481079.
11. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. 2009. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728-740.
12. Spreen WR, Margolis DA, Pottage JC. 2013. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS 8:565-571. http://dx.doi.org/10.1097/COH.0000000000000002.
13. Dolgin E. 2014. Long-acting HIV drugs advanced to overcome adherence challenge. Nat Med 20:323-324. http://dx.doi.org/10.1038/nm0414-323.
14. Williams J, Sayles HR, Meza JL, Sayre P, Sandkovsky U, Gendelman HE, Flexner C, Swindells S. 2013. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine 8:1807-1813. http://dx.doi.org/10.2217/nnm.12.214.
15. Jackson AG, Else LJ, Mesquita PM, Egan D, Back DJ, Karolia Z, Ringner-Nackter L, Higgs CJ, Herold BC, Gazzard BG, Boffito M. 2014. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV negative volunteers for pre-exposure prophylaxis (PrEP). Clin Pharmacol Ther 96:314-323. http://dx.doi.org/10.1038/clpt.2014.118.
16. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany ABM, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174. http://dx.doi.org/10.1126/science.1193748.
17. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernandez T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallas EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang FR, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363:2587-2599. http://dx.doi.org/10.1056/NEJMoa1011205.
18. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel- Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C, Partners PrEP Study Team. 2012. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367:399-410. http://dx.doi.org/10.1056/NEJMoa1108524.
19. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT, TDF2 Study Group. 2012. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 367:423-434. http://dx.doi.org/10.1056/NEJMoa1110711.
20. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kittimunkong S, Chuachoowong R, Gvetadze RJ, McNicholl JM, Paxton LA, Curlin ME, Hendrix CW, Vanichseni S. 2013. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok tenofovir study): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet 381:2083-2090. http://dx.doi.org/10.1016/S0140-6736(13)61127-7.
21. Cortez JM, Jr, Quintero R, Moss JA, Beliveau M, Smith TJ, Baum MM. 2015. Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants. Antimicrob Agents Chemother 59:59-66. http://dx.doi.org/10.1128/AAC.03906-14.
22. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. 2011. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother 66:240-250. http://dx.doi.org/10.1093/jac/dkq447.
23. Louissaint NA, Cao YJ, Skipper PL, Liberman RG, Tannenbaum SR, Nimmagadda S, Anderson JR, Everts S, Bakshi R, Fuchs EJ, Hendrix CW. 2013. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retrovir 29:1443-1450. http://dx.doi.org/10.1089/aid.2013.0044.
24. Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, Cundy KC. 2005. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 49:1898-1906. http://dx.doi.org/10.1128/AAC.49.5.1898-1906.2005.
25. Markowitz M, Zolopa A, Squires K, Ruane P, Coakley D, Kearney B, Zhong LJ, Wulfsohn M, Miller MD, Lee WA. 2014. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother 69:1362-1369. http://dx.doi.org/10.1093/jac/dkt532.
26. Chen J, Walters K, Ashton P. 2005. Correlation of in vitro-in vivo release rates for sustained release nevirapine implants in rats. J Control Release 101:357-358.
27. Smith TJ, Pearson PA, Blandford DL, Brown JD, Goins KA, Hollins JL, Schmeisser ET, Glavinos P, Baldwin LB, Ashton P. 1992. Intravitreal sustained-release ganciclovir. Arch Ophthalmol 110:255-258. http://dx.doi.org/10.1001/archopht.1992.01080140111037.
28. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD, Heinemann MH, Campbell S, Boddice S, Duker JS, Naughton K, McGeary J, Chong LP, Walonker F, Levin L, Lopez K, Gomes A, Davis JL, Simmons T, Vandenbrook R, Fish RH, Hutchison C, Ai E, Luckie A, Tashayyod D, Anand R, Chuang EL, Lawrence B, Robinson MR, Champagne K, Cantrill HL, Brallier A, Freeman WR, Jarman C, Wieland MR, Coverstone V, Ligh JK, Hutt R, Norman BC, Cristiano J, Neger R, Crawford K, Weinberg DV, Munana A, Murphy FP, Pace B, Duh YJ, Gordon JE, Johnson PJ, Lee JA, Pang CF, Safyan E, Seidl NL, Stoecker JF, Ashton P, Smith TJ, Armstrong J, Brothers R, Hubbard L, Dieterich DT, Frost KR, Maguire MG, Nussenblatt RB, Sanborn GE. 1997. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 337:83-90. http://dx.doi.org/10.1056/NEJM199707103370203.
29. Baum MM, Butkyavichene I, Gilman J, Kennedy S, Kopin E, Malone AM, Nguyen C, Smith TJ, Friend DR, Clark MR, Moss JA. 2012. An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci 101:2833-2843. http://dx.doi.org/10.1002/jps.23208.
30. Gunawardana M, Baum MM, Smith TJ, Moss JA. 2014. An intravaginal ring for the sustained delivery of antibodies. J Pharm Sci 103:3611-3620. http://dx.doi.org/10.1002/jps.24154.
31. th ed. The National Academies Press, Washington, DC.
32. U.S. FDA. 2001. Guidance for industry: bioanalytical method validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Rockville, MD.
33. Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, Salata R, Soto-Torres L, Patterson K, Minnis AM, Gandham S, Gomez K, Richardson BA, Bumpus NN. 2013. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 8:e55013. http://dx.doi.org/10.1371/journal.pone.0055013.
34. Chapman EH, Kurec AS, Davey FR. 1981. Cell volumes of normal and malignant mononuclear cells. J Clin Pathol 34:1083-1090. http://dx.doi.org/10.1136/jcp.34.10.1083.
35. Babusis D, Phan TK, Lee WA, Watkins WJ, Ray AS. 2013. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm 10:459-466. http://dx.doi.org/10.1021/mp3002045.
36. Byron PR, Dalby RN. 1987. Effects of heat treatment on the permeability of polyvinyl alcohol films to a hydrophilic solute. J Pharm Sci 76:65-67.
37. Petrova NV, Evtushenko AM, Chikhacheva IP, Zubov VP, Kubrakova IV. 2005. Effect of microwave irradiation on the cross-linking of polyvinyl alcohol. Russ J Appl Chem 78:1158-1161. http://dx.doi.org/10.1007/s11167-005-0470-1.
38. Kis O, Robillard K, Chan GNY, Bendayan R. 2010. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 31:22-35. http://dx.doi.org/10.1016/j.tips.2009.10.001.
39. Madrasi K, Burns RN, Hendrix CW, Fossler MJ, Chaturvedula A. 2014. Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism. CPT Pharmacometrics Syst Pharmacol 12:e147. http://dx.doi.org/10.1038/psp.2014.46.
40. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, Cohen MS, Kashuba ADM. 2011. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 3:112re114. http://dx.doi.org/10.1126/scitranslmed.3003174.
41. Hendrix CW. 2013. Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design. Cell 155: 515-518. http://dx.doi.org/10.1016/j.cell.2013.09.030.
42. Trezza CR, Kashuba ADM. 2014. Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention. Clin Pharmacokinet 53:611-624. http://dx.doi.org/10.1007/s40262-014-0148-z.
43. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapia M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallas EG, Grant RM, iPrEx Study Team. 2012. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 4:151ra125. http://dx.doi.org/10.1126/scitranslmed.3004006.
44. West GB, Brown JH. 2005. The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J Exp Biol 208:1575-1592. http://dx.doi.org/10.1242/jeb.01589.
45. Sharma V, McNeill JH. 2009. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157:907-921. http://dx.doi.org/10.1111/j.1476-5381.2009.00267.x.
46. Merck & Co, Inc. 2014. Nexplanon prescribing information. Merck Sharp & Dohme B.V., Whitehouse Station, NJ.